Freenome (NASDAQ:FRNM) Stock Rating Upgraded by Wall Street Zen

Freenome (NASDAQ:FRNM) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

FRNM has been the topic of a number of other reports. Weiss Ratings began coverage on shares of Freenome in a research note on Monday, August 24th. They issued a “sell (d+)” rating on the stock. Leerink Partners began coverage on Freenome in a research note on Friday, August 14th. They set an “outperform” rating and a $18.00 target price on the stock. Guggenheim initiated coverage on shares of Freenome in a report on Thursday, August 20th. They set a “buy” rating and a $21.00 target price on the stock. TD Cowen started coverage on Freenome in a research note on Tuesday, August 18th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on Freenome in a research report on Monday, August 17th. They set a “buy” rating and a $17.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Freenome Stock Performance

Shares of NASDAQ FRNM opened at $15.99 on Friday. Freenome has a 52-week low of $9.97 and a 52-week high of $17.50. The stock has a market capitalization of $1.72 billion, a PE ratio of -266.46 and a beta of 0.48.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. Its approach combines artificial intelligence with multiomics analysis, examining biological signals in blood, including circulating tumor material and other molecular indicators.

The company has focused on noninvasive screening tests for colorectal cancer and other cancers. Freenome’s products remain in development and are being evaluated through clinical research and validation studies; the company’s tests are not described here as broadly approved diagnostic products.

Founded in 2014 and headquartered in the United States, Freenome has worked with healthcare providers, research organizations and pharmaceutical companies to advance its screening technology.